文献速递神经肿瘤功能神经外科

陀螺旋转向放射外科:逾500个治疗肿瘤的临床经验与前瞻性分析

Gyroscopic Radiosurgery: Clinical Experience and Prospective Analysis of over 500 Treated Tumors.
PubMed 文献 · World Neurosurg · 2025-11-28

该前瞻性研究纳入2021至2024年接受陀螺旋转向放射外科(GRS)治疗的颅内肿瘤患者,分析有至少1次影像和临床随访的382例患者共541个肿瘤。多数为前庭神经鞘瘤(196)、脑转移瘤(188)和脑膜瘤(113)。脑转移瘤中位处方剂量20 Gy,脑膜瘤15 Gy,前庭神经鞘瘤13 Gy。中位影像随访10.6个月,多数肿瘤体积缩小或稳定,显示早期疗效与安全性。

要点

  • GRS治疗颅内肿瘤具有高度适形性和陡峭剂量梯度。
  • 脑转移瘤中位处方剂量20 Gy,脑膜瘤15 Gy,前庭神经鞘瘤13 Gy。
  • 中位影像随访10.6个月,多数肿瘤早期体积缩小或稳定。

核心结论

  • GRS自屏蔽治疗平台早期结果显示有效且安全。

研究设计与样本

  • 前瞻性研究,纳入2021至2024年接受GRS的颅内肿瘤患者,分析382例患者共541个肿瘤。

主要发现

  • 治疗肿瘤中前庭神经鞘瘤196个、脑转移瘤188个、脑膜瘤113个。
  • 脑转移瘤中位处方剂量20 Gy,脑膜瘤15 Gy,前庭神经鞘瘤13 Gy。
  • 剂量学分析显示GRS治疗高度适形,达到陡峭剂量梯度。
  • 中位影像随访10.6个月,多数肿瘤体积缩小或稳定。

关键数值与推荐

  • 脑转移瘤中位处方剂量20 Gy。
  • 脑膜瘤中位处方剂量15 Gy。
  • 前庭神经鞘瘤中位处方剂量13 Gy。

临床怎么用

  • GRS可用于颅内肿瘤的放射外科治疗,早期影像随访显示多数肿瘤控制良好。

局限性

  • 随访时间有限,需要未来研究提供长期结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery plays a significant role in the treatment of various benign and malignant tumors of the central nervous system. Recently, the first self-shielding treatment platform for gyroscopic radiosurgery (GRS) was introduced. Herein, we report our experience with GRS treatment of the first 541 tumors in a prospective setting. METHODS: This study enrolled patients who underwent GRS for intracranial tumors. Patient, treatment, and outcome data were prospectively collected and analyzed. Only patients with at least 1 imaging and clinical follow-up were included in this analysis. Volumetric assessments and major toxicity are presented. RESULTS: A total of 491 patients were treated between 2021 and 2024. Of those, 382 patients harboring 541 tumors underwent at least 1 imaging and clinical follow-up. The majority of tumor entities treated were vestibular schwannomas (196), brain metastases (188), and meningiomas (113). The median prescription dose for brain metastases was 20 Gy. For meningiomas and vestibular schwannomas, the median prescription doses were 15 and 13 Gy, respectively. Analysis of dosimetric performance showed that GRS treatments are highly conformal, achieving steep dose gradients. The median imaging follow-up was 10.6 months. Volumetry of the treated targets demonstrated an early treatment response with either volume reduction or stability for most tumors. CONCLUSIONS: The early results of this prospective study, show the efficacy and safety of the new self-shielding treatment platform. Due to the limited follow-up of this analysis, future studies including long-term outcome data are needed.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Santacroce A, Muacevic A, Kohlhase N, et al. Gyroscopic Radiosurgery: Clinical Experience and Prospective Analysis of over 500 Treated Tumors. World Neurosurg. 2025. PMID: 41318094. doi:10.1016/j.wneu.2025.124684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。